Streetbeat News

Products Services

BHVN

Biohaven Ltd. reported its Q3 2024 financial results, highlighting $642 million in cash and securities. The company achieved positive trial results for troriluzole in spinocerebellar ataxia, with plans for an NDA re-submission. Biohaven is advancing multiple drug programs, including taldefgrobep alfa for spinal muscular atrophy and obesity, and BHV-2100 for migraine and neuropathic pain.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

KNSA

Kiniksa Pharmaceuticals (Nasdaq: KNSA) will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on November 19, 2024.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

LYRA

Lyra Therapeutics, a clinical-stage biotechnology company, reported its Q3 2024 financial results and provided a corporate update. The company is focused on developing long-acting, anti-inflammatory sinonasal implants for chronic rhinosinusitis.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

GUTS

Fractyl Health, Inc. (Nasdaq: GUTS) reported its Q3 2024 financial results and provided updates on its weight maintenance and diabetes treatment studies. Key data releases are expected in late 2024 and mid-2025.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

ATRA

Atara Biotherapeutics reported its Q3 2024 financial results and operational progress, highlighting the enrollment of the first patient in their Phase 1 NHL trial of ATA3219.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

DRCT

Direct Digital Holdings (Nasdaq: DRCT) reported its Q3 2024 financial results and announced the launch of Colossus Connections to enhance integration with demand-side platforms. The company also introduced a new buy-side operating structure to create additional business lines and revenue opportunities. A conference call is scheduled for 5:00 PM ET.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

IBIO

iBio has reported its fiscal first quarter 2025 financial results and announced progress in its myostatin program, with dosing now underway in a non-human primate study.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

APYX

Apyx Medical Corporation announced that its President and CEO, Charles Goodwin, and CFO, Matt Hill, will attend the 15th Annual Craig-Hallum Alpha Select Conference. Apyx Medical is known for its Renuvion® technology.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

ECOR

ElectroCore, Inc. (Nasdaq: ECOR) has received the Men's Health Magazine Tech Award for its wellness product, Truvaga Plus. This award recognizes innovation and excellence in health technology, highlighting the product's significant impact on men's health and wellness.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

RCKT

Rocket Pharmaceuticals will present updated data from its Phase 1 clinical trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions.

Portfolio Pulse from

November 12, 2024 | 9:15 pm